...
首页> 外文期刊>Veterinary and Comparative Oncology >Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy. (Special Issue: Tyrosine kinase inhibitors.)
【24h】

Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy. (Special Issue: Tyrosine kinase inhibitors.)

机译:受体酪氨酸激酶抑制剂:用于兽医癌症治疗的分子靶向药物。 (特刊:酪氨酸激酶抑制剂。)

获取原文
获取原文并翻译 | 示例
           

摘要

Tyrosine kinases (TKs) are key mediators of signalling pathways in cells. Located at the surface of the cell, within the cytoplasm or in the nucleous, TKs have been showed to be involved in regulation of normal cellular processes and also play an important role in the development, progression and spread of several types of cancer. Seventy percent of TK's are Receptor Tyrosine Kinases and these have become key targets for cancer therapy. This short synopsis is intended to give the reader an introduction to this area of targeted therapy for cancer as a prelude to this special edition of Veterinary and Comparative Oncology.CAS Registry Numbers 60-18-4
机译:酪氨酸激酶(TKs)是细胞中信号通路的关键介体。 TKs位于细胞表面,细胞质内或核仁中,已被证明参与正常细胞过程的调节,并且在几种类型的癌症的发生,发展和扩散中也起着重要作用。 TK的70%是酪氨酸受体激酶,这些已成为癌症治疗的主要靶标。本简短摘要旨在为读者介绍这一针对癌症的靶向治疗领域,以作为此版兽医和比较肿瘤学特别版的序言。CAS注册号60-18-4

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号